Translator Disclaimer
1 July 2011 PHARMACOKINETICS OF MOXIDECTIN IN THE SOUTHERN HAIRY-NOSED WOMBAT (LASIORHINUS LATIFRONS)
Author Affiliations +
Abstract

Sarcoptic mange, caused by Sarcoptes scabiei var. wombati, could be a significant threat to populations of southern hairy-nosed wombats (Lasiorhinus latifrons; SHNW) in Australia. Treatment is currently based on the off-label use of various parasiticidal drugs, with limited clinical efficacy trials. Our primary aim was to determine the pharmacokinetic parameters of a macrocyclic lactone, moxidectin, to assist in the development of effective treatment protocols. Pharmacokinetic parameters were determined in four female SHNW following a single subcutaneous injection of 0.2 mg/kg moxidectin. Blood samples were collected for 38 days following injection (August–September 2008), for analysis using liquid chromatography and tandem mass spectrometry. The mean peak plasma concentration occurred at 13.6 hr, with a mean peak plasma level of 98.6 ng/ml. The mean elimination half-life was 5.03 days, resulting in a mean area under the curve of 377 ng.day/ml. The peak plasma moxidectin concentration was higher than that seen in livestock species but the plasma elimination half-life was shorter. This study suggests that a single injection of 0.2 mg/kg moxidectin may not be sufficient to clear a mange infection in this species.

Clare E. Death, David A. Taggart, Desmond B. Williams, Robert Milne, David J. Schultz, Carlysle Holyoake, and Kristen S. Warren "PHARMACOKINETICS OF MOXIDECTIN IN THE SOUTHERN HAIRY-NOSED WOMBAT (LASIORHINUS LATIFRONS)," Journal of Wildlife Diseases 47(3), 643-649, (1 July 2011). https://doi.org/10.7589/0090-3558-47.3.643
Received: 30 October 2010; Accepted: 1 March 2011; Published: 1 July 2011
JOURNAL ARTICLE
7 PAGES


SHARE
ARTICLE IMPACT
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top